Ras and ERK1/2 Protein Expression in Cancer Tissues of Patients with Type 2 Diabetes Mellitus and Colorectal Cancer: Significance and Correlation with Lymph Node Metastasis and Survival
NIU Shu, DONG Lina, et al
The People's Hospital of Shijiazhuang, Hebei Shijiazhuang 050011, China
Abstract:Objective: To investigate the expression levels of Ras-ERK1/2 signaling in patients with type 2 diabetes mellitus (T2DM) and colorectal cancer (CRC), analyze their relationship with lymph node metastasis, and explore their correlation with survival status. Methods: A total of 59 patients who underwent colorectal cancer surgery at People's Hospital of Shijiazhuang from March 2019 to January 2021 were selected. Patients were divided into the diabetes group (n=29) and non-diabetes group (n=30) based on the presence of concurrent diabetes. Immunohistochemical methods were used to detect the expression levels of Ras and ERK1/2 proteins in surgically resected cancer tissues. Differences in lymph node metastasis were analyzed using the Log-rank test. All patients were followed up for 36 months, and survival conditions were statistically compared. The Spearman correlation analysis was used to analyze the correlation between Ras and ERK1/2 expression and survival period. Results: Ras and ERK1/2 were expressed in both CRC and CRC combined with T2DM, mainly concentrated in the cytoplasm of cancer cells. Compared with the non-diabetes group, the positive expression rates of Ras and ERK1/2 in the CRC combined with T2DM group were significantly increased (P<0.05). The lymph node metastasis rate in the CRC combined with T2DM group was significantly higher than that in the pure CRC group (P<0.05). Compared with the Ras and ERK1/2 negative expression group, the lymph node metastasis rate was significantly higher in the Ras and ERK1/2 positive expression group (P<0.05). The Spearman correlation analysis showed that the protein expression of Ras and ERK1/2 in colorectal cancer patients was negatively correlated with median survival time (P<0.05). Conclusion: Positive expression of Ras-ERK1/2 proteins is positively correlated with lymph node metastasis and negatively correlated with the survival period of colorectal cancer patients, making it an important target for early diagnosis and prognosis assessment.
牛姝, 董丽娜, 吴笛, 冯岚, 张梦瑶, 孙政, 赵志刚, 郝慧斌. 2型糖尿病合并结直肠癌患者癌组织中Ras ERK1/2蛋白表达及意义[J]. 河北医学, 2023, 29(12): 1973-1978.
NIU Shu, DONG Lina, et al. Ras and ERK1/2 Protein Expression in Cancer Tissues of Patients with Type 2 Diabetes Mellitus and Colorectal Cancer: Significance and Correlation with Lymph Node Metastasis and Survival. HeBei Med, 2023, 29(12): 1973-1978.
[1] 牛姝,张宁,王媛,等.P-ERK1/2在2型糖尿病合并结直肠癌患者癌组织中的表达及意义[J].河北医药,2022,44(6):824-828. [2] Slack C.Ras signaling in aging and metabolic regulation[J].Nutr Healthy Aging,2017,4(3):195-205. [3] Schlessinger J.Cell signaling by receptor tyrosine kinases[J].Cell,2000,103(2):211-225. [4] Bosman F T,Cameiro F,Hruban R H,et al.World health organization classification of tumours of the digestive system[M].Lyon:IARC Press,2010. [5] Ling S,Brown K,Miksza J K,et al.Association of type 2 diabetes with cancer:a meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people[J].Diabetes Care,2020,43,2313-2322. [6] Giouleme O,Diamantidis M D,Katsaros M G.Is diabetes a causal agent for colorectal cancer Pathophysiological and molecular mechanisms[J].World Gastroenterol,2011,17,444-448. [7] Hua F,Yu J J,Hu Z W.Diabetes and cancer,common threads and missing links[J].Cancer Lett,2016,374,54-61. [8] Ryu T Y,Park J,Scherer P E.Hyperglycemia as a risk factor for cancer progression[J].Diabetes Metab,2014,38,330-336. [9] Samatar AA,Poulikakos PI.Targeting RAS-ERK signalling in cancer:promises and challenges[J].Nat Rev Drug Discov,2014,13(12):928-942. [10] Drosten M,Barbacid M.Targeting the MAPK pathway in KRAS-driven tumors[J].Cancer Cell,2020,37(4):543-550. [11] Luo J,Lin H C,He K,et al.Diabetes and prognosis in older persons with colorectal cancer[J].Br Cancer,2014,110 (7):1847-1854.